For the first time ever, researchers have uncovered an exact blend of nutrients to significantly lower intraocular pressure. The exclusive, patent-pending Mirtogenol®, available now in new Ocular Pressure & Retina Defense, combines the highest-quality extracts of bilberry and pine bark.

The Mirtoselect® Bilberry is the best on the market. With a high concentration of anthocyanosides, or super-antioxidants, Mirtoselect Bilberry increases microcirculation. Pycnogenol® Maritime French Pine extract is cultivated from the pines that thrive along the coast of France. The extract from these trees has been shown most effective in improving intraocular pressure and blood flow.

Two clinical studies show impressive results with Mirtogenol

Mirtogenol has been the subject of two clinical studies. One study, using 120 mg of Mirtogenol, lowered intraocular pressure by a significant 9 points. In a second study using 240 mg of Mirtogenol, 19 out of 20 people saw a reduction in intraocular pressure where only 1 out of 18 subjects in the control group saw a difference.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

‡Mirtogenol® is a registered trademark of Horphag Research and Indena and is protected by international and pending patents.
♦Mirtoselect® is a registered trademark of Indena S.p.A.
Pycnogenol® is a registered trademark of Horphag Research Ltd.

Dosage:Take 1–2 capsules daily.Note:This product is not recommended for children.

Side Effects:There are no known side effects associated with this product. However, as with any food product, there may be infrequent and highly sensitized reactions associated with this or any other nutritional supplement. If such a reaction occurs, you should consider discontinuing use of this or any product.

Warnings:This product is not a treatment for glaucoma.If you are lactating, pregnant or planning to become pregnant, consult a health care professional before taking this product. Stop use if allergic reaction occurs.Keep out of reach of children.

Scientific Support

Researchers divided 38 subjects to either supplementation with 240 mg of Mirtogenol daily, or no treatment at all. Subjects were followed for 6 months. Blood flow in the central retinal artery, ophthalmic artery and posterior ciliary artery all increased in the Mirtogenol group after 3 and 6 months of treatment.1

In a second trial, researchers examined the effect of Mirtogenol (120 mg/day) on intraocular pressure in 79 healthy subjects for 6 months. Similar results were seen with ocular blood flow, with Mirtogenol increasing blood flow.2